"Oral tirzepatide" is searched as if it were a product. It is not one: no tirzepatide tablet, capsule or drop has been approved anywhere a label could be found, and the human evidence on swallowing it fits in one company press release. What does exist is a shelf of compounded sublingual drops and troches, a small capsule study, a dog study, and an approved oral weight-loss pill from Lilly that contains a different drug. This page reports each (read 2026-10-07) and works out what an oral milligram means once absorption is counted. It describes; it does not advise.
The injected doses, the label steps and the vial arithmetic are on the tirzepatide dosage page; the same route question for semaglutide, which does have approved tablets, is on oral semaglutide.
What is approved, and what is not
| Product | Molecule | Route | Label status (read 2026-10-07) |
|---|---|---|---|
| ZEPBOUND, MOUNJARO | Tirzepatide | Subcutaneous injection | FDA-labelled; bioavailability 80% |
| FOUNDAYO | Orforglipron | Tablet, once daily | FDA-labelled for weight reduction; 0.8 mg to 17.2 mg |
| Compounded sublingual drops, troches, ODTs | Tirzepatide | Under the tongue or swallowed | No label; no human data |
| DehydraTECH-tirzepatide capsules | Tirzepatide | Swallowed | Investigational; one company-reported study |
The FOUNDAYO row answers a search that often lands on "oral tirzepatide". Its label lists a 0.8 mg start, monthly steps to 2.5, 5.5, 9, 14.5 and a maximum of 17.2 mg once daily, and an absolute bioavailability of 77%. That figure is possible because orforglipron is a small molecule, not a peptide; it says nothing about what happens when tirzepatide, a 39-amino-acid peptide with a molecular weight of 4,813 (PubChem), is swallowed.
The one human study of swallowed tirzepatide
Lexaria Bioscience, which makes an oral delivery technology called DehydraTECH, ran a randomised crossover study (GLP-1-H24-3) in which 9 healthy adults completed both arms: 20 mg of tirzepatide in its capsules once daily for seven days, and a single 2.5 mg Zepbound injection, separated by a four- to six-week washout. Its release of 2025-01-14 reports that the capsules reached "roughly equal" end-of-study blood levels, with levels still rising on day 8 rather than peaking on day 2 as after the injection, and fewer reported adverse events. The company described a follow-on 12-week arm in Australia at 20 mg daily rising to roughly twice that.
Three limits are the company's own numbers. Nine people, eight days and one injected comparison dose is a pharmacokinetic signal, not a dosing record. The results appear in a press release; the matching registry record (NCT06648031, completed 2025-07-31) had no results posted when read. And the capsule is a specific formulation; its result transfers to no other oral or sublingual product.
Why an oral milligram is not an injected one
The arithmetic from the release's figures:
| Route | Weekly amount | Share absorbed | Absorbed per week (arithmetic) |
|---|---|---|---|
| Zepbound injection 2.5 mg weekly | 2.5 mg | 80% (label) | ≈2.0 mg |
| DehydraTECH capsules 20 mg daily | 140 mg | not published | — |
| Implied, if both reach similar levels | 140 mg | ≈1.4% | ≈2.0 mg |
That implied 1 to 2% is in the same range the semaglutide tablet labels print for their own absorption enhancer, which suggests the order of magnitude is right. It is still an inference by this site: the company did not publish an absolute bioavailability, and "roughly equal" end-of-study levels after one injection and seven capsules are not a steady-state comparison. A 56-fold difference in swallowed mass for a similar blood level is the one firm lesson.
Sublingual drops and compounded forms
Compounded tirzepatide drops and troches became common after the tirzepatide shortage ended and pharmacies could no longer copy the approved injection. A survey of compounding websites between February and March 2025 found 33 products differing from approved forms, a third containing tirzepatide; the 17 with a single active ingredient were sublingual (82%) or orally disintegrating tablets (18%), and only 18% reported beyond-use date and storage information (Belcourt et al., Annals of Pharmacotherapy 2026, PMID 41689811). The authors saw "a rationale" for such forms but no evidence of benefit over approved oral tablets.
For tirzepatide under the tongue there is no published study in any species: PubMed returned two records for "sublingual tirzepatide" on 2026-10-07, the compounding survey above and a review, neither with pharmacokinetic data, and ClinicalTrials.gov returned none. The closest data are for semaglutide, where a compounding-industry laboratory found 0.29% to 0.34% relative bioavailability under the tongue in rats, set out on the oral semaglutide page. A labelled milligram figure on a dropper bottle therefore has no measured relationship to an injected dose.
Tablets in development
A 2026 formulation paper built immediate-release tirzepatide tablets with sodium caprate, the absorption enhancer used in some oral peptide programmes, and tested them in beagle dogs: the 300 mg-enhancer tablet reached a peak of 46.49 ± 23.79 ng/mL and outperformed the 500 mg version (Im et al., Pharmaceutics 2026, PMID 42514904). The wide standard deviation, close to half the mean, is typical of oral peptides and is the same variability the semaglutide tablet label reports in people. No human tirzepatide tablet trial was registered on 2026-10-07.
What is not established
No source gives a dose of oral or sublingual tirzepatide that matches any injected step, no label covers any tirzepatide taken by mouth, and no peer-reviewed human study exists. A lyophilised research vial is made to be reconstituted and injected; its contents taken by mouth would have no absorption enhancer and no measured bioavailability. Injected amounts in syringe units are on tirzepatide units, and the compound itself is covered in Medibact's Tirzepatide guide. Nothing on this page is an instruction; product, route and amount belong with a prescriber.
Sources and dates
Opened 2026-10-07: the ZEPBOUND label via openFDA (effective 2026-08-28), section 12.3; the FOUNDAYO label via DailyMed (set id 8ac446c5-feba-474f-a103-23facb9b5c62, published 2026-08-13) and openFDA, sections 1, 2 and 12.3; Lexaria Bioscience's release of 2025-01-14 on study GLP-1-H24-3; ClinicalTrials.gov records NCT06648031 and searches for "oral tirzepatide" and "sublingual tirzepatide"; PubMed records 42514904 and 41689811 (abstracts read); PubChem's tirzepatide record (molecular weight 4,813). Absorbed amounts and ratios are arithmetic by this site. Corrections go to the contact page.